These effects were reversed by CV or CV-LN treatment, which improve synaptic function and BDNF expression (Table 3), confirming the important role of CV and CV-LN in the modulation of the SIRT1/miRNA-134/GSK3β axis in AD. This evidence concerns the gene GSK3B and Alzheimer disease.